Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy

Tas, Faruk; Karabulut, Senem; Ciftci, Rumeysa; Sen, Fatma; Sakar, Burak; Disci, Rian; Duranyildiz, Hadiye

doi:10.1007/s00280-014-2450-8

Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy

Atıf İçin Kopyala

Tas F., Karabulut S., Ciftci R., Sen F., Sakar B., Disci R., ...Daha Fazla

CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.73, sa.6, ss.1163-1171, 2014 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 73 Sayı: 6
Basım Tarihi: 2014
Doi Numarası: 10.1007/s00280-014-2450-8
Dergi Adı: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1163-1171
Anahtar Kelimeler: LDH, CEA, CA19-9, Metastatic, Pancreatic cancer
İstanbul Üniversitesi Adresli: Evet

Özet

Serum LDH, CEA, and CA19-9 levels are important tumor markers in pancreatic cancer. The purpose of this study was to evaluate the clinical significance of serum LDH, CEA, and CA19-9 levels in metastatic pancreatic cancer (MPC) receiving gemcitabine-based chemotherapy.